The Role of PGE2 in the Induction of Suppressor Cells in Humans

Part of the Prostaglandins, Leukotrienes, and Cancer book series (PLAC, volume 4)


Monocytes and related cells play a key role in regulating the interleukin (IL) cascade leading to T cell proliferation and finally to the immune response. They can either amplify the response by producing IL1 (1) or shut it down, mainly by releasing prostaglandin E2 (PGE2) (2,3). It has clearly been demonstrated that monocytes can produce sufficient levels of PGE2 to inhibit all types of immune responses (4–6). PGE2 acts primarily through the suppression of IL2 production by T lymphocytes (7,8), but some experimental results also suggest the possible interference of PGE2 with IL2-dependent proliferation (9). The PGE2 effect has been shown to be associated with a rise in the cyclic AMP (cAMP) level of T lymphocytes (10), although there is no evidence for a direct role of cAMP in mediating PGE2 suppressor activity.


Suppressor Cell Cell Immunol Mixed Leukocyte Reaction Graft Versus Host Suppressor Cell Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mizel SB: Interleukin 1 and T cell activation. Immunol Rev (63): 51–72, 1982.PubMedCrossRefGoogle Scholar
  2. 2.
    Goodwin JS, Bankhurst A, Messner RP: Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin producing suppressor cell. J Exp Med (146): 1719–1734, 1977.PubMedCrossRefGoogle Scholar
  3. 3.
    Kurland JI, Bockman R: Prostaglandin E production by human blood monocytes and mouse peritoneal macrophages. J Exp Med (147): 952–957, 1978.Google Scholar
  4. 4.
    Goodwin JS, Webb DR: Regulation of the immune response by prostaglandins. Clin Immunol Immunopathol (15): 106–122, 1980.PubMedCrossRefGoogle Scholar
  5. 5.
    Wolf M, Droege W: Inhibition of cytotoxic responses by prostaglandin E2 in the presence of interleukin 2. Cell Immunol (72): 286–294, 1982.PubMedCrossRefGoogle Scholar
  6. 6.
    Kurland JI, Kincade PW, Moore MAS: Regulation of B lymphocyte clonal proliferation by stimulatory and inhibitory macrophage-derived factors. J Exp Med (146): 1420–1427, 1977.PubMedCrossRefGoogle Scholar
  7. 7.
    Rappaport RS, Dodge GR: Prostaglandin E inhibits the production of human interleukin 2. J Exp Med (155): 943–948, 1982.Google Scholar
  8. 8.
    Walker C, Kristensen F, Bettens F, deWeck AL: Lymphokine regulation of activated 1(G1) lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2 production. J Immunol (130): 1770–1773, 1983.PubMedGoogle Scholar
  9. 9.
    Baker PE, Fahey JV, Munik A: Prostaglandin inhibition of T cell proliferation is mediated at two levels. Cell Immunol (61): 52–61, 1981.PubMedCrossRefGoogle Scholar
  10. 10.
    Scott RE: Effects of prostaglandins, epinephrine and NaF on human leukocyte, platelet and liver adenylcyclase. Blood (35): 514–521, 1970.PubMedGoogle Scholar
  11. 11.
    Goodwin JS, Messner RP, Bankhurst AD, Peake GT, Saiki JH, Wiliams RC Jr: Prostaglandin-producing suppressor cells in Hodgkin’s disease. N Engi J Med (197): 263–269, 1977.Google Scholar
  12. 12.
    Plescia OJ, Smith AH, Grinwich K: Subversion of the immune response by tumor cells and the role of prostaglandins. Proc Natl Acad Sci USA (72): 1848–1851, 1975.PubMedCrossRefGoogle Scholar
  13. 13.
    Stobo JD, Kennedy MS, Goldyne ME: Prostaglandin E modulation of the mitogenic response of human T cells. Differential response of T-cell subpopulations. J Clin Invest (64): 1188–1203, 1979.Google Scholar
  14. 14.
    Goodwin JS, Kaszubowski PA, Williams RC Jr: Cyclic adenosine monophosphate response to prostaglandin E2 in subpopulations of human lymphocytes. J Exp Med (150): 1260–1267, 1979.PubMedCrossRefGoogle Scholar
  15. 15.
    Goodwin JS, Messner RP, Peake GT: Prostaglandin suppression of mitogen-stimulated lymphocytes in vitro. J Clin Invest (62): 753–760, 1978.PubMedCrossRefGoogle Scholar
  16. 16.
    Fischer A, Durandy A, Griscelli C: Role of prostaglandin E2 in the induction of nonspecific T lymphocyte suppressor activity. J Immunol (126): 1452–1455, 1981.PubMedGoogle Scholar
  17. 17.
    Webb DR, Nowowiejski I: Mitogen induced changes in lymphocyte prostaglandin levels: a signal for the induction of suppressor cell activity. Cell Immunol (41): 72–78, 1978.PubMedCrossRefGoogle Scholar
  18. 18.
    Rogers TJ, Nowowiejski I, Webb DR: Partial characterization of a prostaglandin-induced suppressor factor. Cell Immunol (50): 82–89, 1980.PubMedCrossRefGoogle Scholar
  19. 19.
    Rogers TJ, Campbell L, Calhoon K, Nowowiejski I, Webb DR: Suppression of B-cell and T-cell responses by the prostaglandin induced T cell derived suppressor (PITS). Cell Immunol (66): 269–276, 1982.PubMedCrossRefGoogle Scholar
  20. 20.
    Delfraissy JF, Galanaud P, Wallon C, Balavoine JF, Dormont J: Abolished in vitro antibody response in elderly: exclusive involvement of prostaglandin-induced T suppressor cells. Clin Immunol Immunopathol (24): 377–385, 1982.PubMedCrossRefGoogle Scholar
  21. 21.
    Kaszubowski P, Goodwin JS: Monocyte-produced prostaglandin induces Fc gamma receptor expression in human T cells. Cell Immunol (68): 343–349, 1982.PubMedCrossRefGoogle Scholar
  22. 22.
    Chouaib S, Fradelizi D: The mechanism of inhibition of human interleukin 2 production. J Immunol (129): 2463–2468, 1982.PubMedGoogle Scholar
  23. 23.
    Donnely RP, Rogers TJ: Inhibitors of prostaglandin synthesis block the induction of staphylococcal enterotoxin B-activated T-suppressor cells. Cell Immunol (81): 61–70, 1983.CrossRefGoogle Scholar
  24. 24.
    Fradelizi D, Chouaib S: Regulation of IL2 production in man. Abstract from the symposium of the French Society of Immunology on Interleukins 1983, p. 12.Google Scholar
  25. 25.
    Melmon KL, Weinstein Y, Shearer GM, Bourne HR, Bauminger S: Separation of specific antibody-forming mouse cells by their adherence to insolubilized endogenous hormones. J Clin Invest (53): 22–35, 1974.PubMedCrossRefGoogle Scholar
  26. 26.
    Goodwin JS, Wiik A, Lewis M, Bankhurst AD, Williams RC Jr: High affinity binding sites for prostaglandin E on human lymphocytes. Cell Immunol (43): 150–158, 1979.CrossRefGoogle Scholar
  27. 27.
    Fischer A, LeDeist F, Durandy A, Griscelli C: Separation of a population of human T lymphocytes which bind prostaglandin E2 and exert a suppressor activity. Submitted for publication, 1984.Google Scholar
  28. 28.
    Gaulde N, Goodwin JS: Effects of prostaglandin E2 and pre-incubation on lectin-stimulated proliferation of human T cell subsets. Cell Immunol (70): 373–380, 1982.CrossRefGoogle Scholar
  29. 29.
    Emilie D, Crevon MC, Galanaud P: Prostaglandin E2 regulation of human specific B cell response: interaction with a monocyte product. Clin Immunol Immunopathol (29): 415–423, 1983.PubMedCrossRefGoogle Scholar
  30. 30.
    Ceuppens J, Goodwin JS: Endogenous prostaglandin E enhances polyclonal immunoglobulin production by tonically inhibiting T suppressor cell activity. Cell Immunol (70): 41–54, 1982.Google Scholar
  31. 31.
    Yoneda T, Mundy GR: Monocytes regulate osteoclast activating factor production by releasing prostaglandin. J Exp Med (150): 338–351, 1979.PubMedCrossRefGoogle Scholar
  32. 32.
    Herscowitz HB, Sakane T, Steinberg AD, Green I: Heterogeneity of human suppressor cells induced by concanavalin A as determined in simultaneous assays of immune function. J Immunol (124): 1403–1410, 1980.PubMedGoogle Scholar
  33. 33.
    Palacios R, Möller G: T cell growth factor abrogates Con A-induced suppressor cell function. J Exp Med (153): 1360–1365, 1981.PubMedCrossRefGoogle Scholar
  34. 34.
    Greene WC, Fleisher TA, Waldmann TA: Soluble suppressor supernatants elaborated by concanavalin A-activated human mononuclear cells. I. Characterization of a soluble suppressor T cell proliferation. J Immunol (126): 1185–1191, 1981.PubMedGoogle Scholar
  35. 35.
    Fleisher TA, Greene WC, Blaese RM, Waldmann TA: Soluble suppressor supernatants elaborated by concanavalin A-activated human mononuclear cells. II. Characterization of a soluble suppressor of B cell immunoglobulin production. J Immunol (126): 1192–1197, 1981.PubMedGoogle Scholar
  36. 36.
    Goodwin JS: Modulation of concanavalin A induced suppressor cell activation by prostaglandin E2. Cell Immunol (49): 421–425, 1980.PubMedCrossRefGoogle Scholar
  37. 37.
    Rocklin RE: Modulation of cellular immune responses in vivo and in vitro by histamine receptor-bearing lymphocytes. J Clin Invest (57):1051–1060, 1976.CrossRefGoogle Scholar
  38. 38.
    Beer DJ, Rosenwasser LJ, Dinarello CA, Rocklin R: Cellular interactions in the generation and expression of histamine-induced suppressor activity. Cell Immunol (69): 101–112, 1982.PubMedCrossRefGoogle Scholar
  39. 39.
    Durandy A, Fischer A, Griscelli C: Active suppression of B lymphocyte maturation by two different newborn T lymphocyte subsets. J Immunol (123): 2644–2650, 1979.PubMedGoogle Scholar
  40. 40.
    Hayward AR, Lydyard PM: Suppression of B lymphocyte differentiation by newborn T lymphocytes with an Fc receptor for IgM. Clin Exp Immunol (34): 374–378, 1978.PubMedGoogle Scholar
  41. 41.
    Fischer A, Durandy A, Mamas S, McCall E, Dray F, Griscelli C: Lack of prostaglandin E2-mediated monocyte suppressive activity in newborn and mothers. Clin Exp Immunol (49): 377–385, 1982.PubMedGoogle Scholar
  42. 42.
    Durandy A, Fischer A, Griscelli C: Inability of newborns or pregnant women’s monocytes to suppress pokeweed mitogeninduced responses. J Immunol (128): 525–529, 1982.PubMedGoogle Scholar
  43. 43.
    Durandy A, Fischer A, Mamas S, Dray F, Griscelli C: Respective roles and interactions of T-lymphocyte and PGE2 mediated monocyte suppressive activities in human newborns and mothers at the time of delivery. Am J Reprod Immunol (2): 127–134, 1982.PubMedGoogle Scholar
  44. 44.
    Kleinhenz ME, Ellner JJ, Spagnuolo PJ, Daniel TM: Suppression of lymphocyte responses by tuberculous plasma and myco-bacterial arabinogalactan. Monocyte dependence and indo-methacin reversibility. J Clin Invest (68): 153–162, 1981.PubMedCrossRefGoogle Scholar
  45. 45.
    Kierszenbaum F: Immunologic deficiency during experimental chagas disease (trypanosoma cruzi infection). J Immunol (129): 2202–2205, 1982.PubMedGoogle Scholar
  46. 46.
    Piessens WF, Partono F, Hoffman SL, Ratiwayanto S, Piessens PW, Falmieri JR, Koiman I, Dennis DT, Carney WP: Antigen specific suppressor T lymphocytes in human lymphatic filariasis. N Engl J Med (307): 144–148, 1982.PubMedCrossRefGoogle Scholar
  47. 47.
    Catanzaro A: Suppressor cells in coccidiomycosis. Cell Immunol (64): 235–245, 1981.PubMedCrossRefGoogle Scholar
  48. 48.
    Howard RJ, Najarian JS: Cytomegalovirus-induced immune suppression. Clin Exp Immunol (18): 109–126, 1974.PubMedGoogle Scholar
  49. 49.
    Rinaldo CR, Carney WP, Richter BS, Black PH, Hirsch MS: Mechanisms of immunosuppression in cytomegaloviral mononucleosis. J Infect Dis (141): 488–495, 1980.PubMedCrossRefGoogle Scholar
  50. 50.
    Kazimiera D, Grinwich KD, Plescia OJ: Tumor mediated immunosuppressor: prevention by inhibitors of prostaglandin synthesis. Prostaglandins (14): 1175–1182, 1977.CrossRefGoogle Scholar
  51. 51.
    Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M: Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. JNCI (64): 1061–1070, 1980.PubMedGoogle Scholar
  52. 52.
    Durandy A, Fischer A, Griscelli C: Dysfunctions of pokeweed mitogen-stimulated T and B lymphocyte responses induced by gammaglobulin therapy. J Clin Invest (67): 867–877, 1981.PubMedCrossRefGoogle Scholar
  53. 53.
    Passwell J, Dayer JM, Merler E: Increased prostaglandin production by human monocytes after membrane receptor activation. J Immunol (123): 115–120, 1979.PubMedGoogle Scholar
  54. 54.
    Tsoi MS: Immunological mechanisms of graft versus host disease in man. Transplantation (33): 459–464, 1982.PubMedCrossRefGoogle Scholar
  55. 55.
    Fischer A, Durandy A, Griscelli C: T lymphocyte and prostaglandin E2-dependent monocyte suppressor activities found in bone marrow transplanted patients. Fifth International Congress of Immunology, Kyoto, 1983.Google Scholar
  56. 56.
    Lapp WS, Mendes M, Kirchner H, Gemsa D: Prostaglandin synthesis by lymphoid tissue of mice experiencing a graft versus host reaction: relationship to immunosuppression. Cell Immunol (50): 271–281, 1980.PubMedCrossRefGoogle Scholar
  57. 57.
    Dy M, Astoin M, Rigaud M, Hamburger J: Prostaglandin (PG) release in the mixed lymphocyte culture; effect of presensitization by a skin allograft; nature of the PG-producing cell. Eur J Immunol (10): 121–126, 1980.PubMedCrossRefGoogle Scholar
  58. 58.
    Fischer A, Munnich A, Saudubray JM, Mamas S, Coude F-X, Charpentier C, Dray F, Frézal F, Griscelli C: Biotin-responsive immunoregulatory dysfunction in multiple carboxylase deficiency. J Clin Immunol (2): 35–38, 1982.PubMedCrossRefGoogle Scholar
  59. 59.
    Staszak CS, Goodwin JS, Troup GM: Decreased sensitivity to prostaglandin and histamine in lymphocytes from normal HLA-B12 individuals: a possible role in auto-immunity. J Immunol (125): 181–185, 1980.PubMedGoogle Scholar
  60. 60.
    Goodwin JS, Messner RP: Prostaglandin E inhibition of mitogen stimulation in patients with multiple sclerosis. Prostaglandins (15): 281–286, 1978.Google Scholar
  61. 61.
    Ladisch S, Holiman B, Poplack DG, Blaese RM: Immuno-deficiency in familial erythrophagocytic lymphohistiocytosis. Lancet (1): 581–614, 1978.PubMedCrossRefGoogle Scholar
  62. 62.
    Fischer A, Durandy A, Griscelli C, Mamas S: Prostaglandin E2-mediated monocyte suppressive activity--role in immunoregulatory disorders in primary immuno-deficiencies. (Seligmann and Hitzig W, eds) North Holland, Elsevier, 1980, pp. 363–372.Google Scholar
  63. 63.
    Ceuppens JL, Rodriguez M, Goodwin JS: Non steroidal anti-inflammatory agents inhibit the synthesis of IgM rheumatoid factor in vitro. Lancet (1): 528–530, 1982.PubMedCrossRefGoogle Scholar
  64. 64.
    Goodwin JS, Dehoratius R, Israel H, Peake GT, Messner RP: Suppressor cell function in sarcoidosis. Ann Intern Med (90): 169–175, 1979.PubMedGoogle Scholar
  65. 65.
    Goodwin JS, Ceuppens JL: Effect of non steroidal anti-inflammatory drugs on immune function. Semin Arthritis Rheum (13): 134–143, 1983.PubMedCrossRefGoogle Scholar
  66. 66.
    Hoffman M: Macrophages and T cells controls distinct phases of B cell differentiation in the humoral immune response in vitro. J Immunol (125): 2076–2080, 1980.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

There are no affiliations available

Personalised recommendations